What is the recommended dose and administration of adenosine for supraventricular tachycardia (SVT) treatment?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 21, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Adenosine Administration for Supraventricular Tachycardia (SVT)

The recommended dose of adenosine for SVT is an initial 6 mg rapid IV bolus, followed by up to two subsequent doses of 12 mg if the initial dose is ineffective, with each dose administered as a rapid bolus over 1-2 seconds followed by a saline flush. 1

Dosing Protocol

Initial Management

  • First-line approach: Vagal maneuvers should be attempted first in hemodynamically stable patients (Class I, Level B-R) 1
  • Adenosine administration:
    • Initial dose: 6 mg rapid IV bolus over 1-2 seconds
    • If no response within 1-2 minutes: 12 mg rapid IV bolus
    • If still no response: May repeat 12 mg dose once more
    • Maximum total: Three doses (6 mg, 12 mg, 12 mg)
    • Safe administration of doses up to 24 mg has been reported in refractory cases 1

Administration Technique

  • Administer as close to the heart as possible (proximal IV site)
  • Follow immediately with a rapid saline flush
  • Patient should be in a supine position during administration
  • Have cardiac monitoring in place

Alternative Pharmacological Options

If adenosine is ineffective or contraindicated:

  • Calcium channel blockers:

    • IV diltiazem: 0.25 mg/kg over 2 minutes, followed by infusion at 5-10 mg/hr
    • IV verapamil: 5-10 mg over 2 minutes, may repeat with 10 mg after 30 minutes 1
  • Beta blockers:

    • IV esmolol: 500 mcg/kg over 1 minute, followed by infusion at 50-300 mcg/kg/min
    • IV metoprolol: 2.5-5.0 mg over 2 minutes, may repeat up to 3 doses 1

Special Considerations

Pregnancy

  • Adenosine is considered safe during pregnancy (Class I, Level C-LD)
  • The short half-life of adenosine (<10 seconds) makes it unlikely to reach fetal circulation 1

Refractory SVT

  • Higher doses of adenosine (up to 24 mg) may be needed in patients with impaired venous return 2
  • If pharmacological therapy fails, synchronized cardioversion is recommended (Class I, Level B-NR) 1

Hemodynamic Instability

  • For hemodynamically unstable patients, proceed directly to synchronized cardioversion (Class I, Level B-NR) 1

Potential Adverse Effects

  • Transient AV block
  • Flushing, chest pain
  • Dyspnea or bronchospasm (rare)
  • Hypotension
  • Potential for initiating atrial fibrillation 1, 3

Important Cautions

  • Contraindications:

    • Second or third-degree AV block (unless patient has functioning pacemaker)
    • Sick sinus syndrome or symptomatic bradycardia
    • Known bronchoconstrictive or bronchospastic lung disease
    • Known hypersensitivity to adenosine 3
  • Drug interactions:

    • Methylxanthines (caffeine, theophylline) can reduce effectiveness
    • Dipyridamole can potentiate adenosine effects 3

Recent Evidence

A 2025 study comparing initial adenosine dosing found that starting with 12 mg was associated with less re-dosing and greater rates of patient improvement compared to starting with 6 mg 4. However, current guidelines still recommend the 6 mg initial dose approach, as this has been established as safe and effective in most patients 1, 5.

Follow-up Management

After successful conversion:

  • Consider oral beta blockers, diltiazem, or verapamil for ongoing management (Class I, Level B-R) 1
  • Electrophysiology study with possible ablation should be considered for definitive treatment (Class I, Level B-NR) 1
  • Educate patients on how to perform vagal maneuvers for future episodes 5

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management of Supraventricular Tachycardia (SVT)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.